Delivery of Stem Cells into Heart Muscle After Heart Attack May Enhance Cardiac Repair and Reverse Injury

NEW YORK (Nov. 19, 2014) —Delivering stem cell factor directly into damaged heart muscle after a heart attack may help repair and regenerate injured tissue, according to a study led by researchers from Icahn School of Medicine at Mount Sinai presented November 18 at the American Heart Association Scientific Sessions 2014 in Chicago, IL.

VEITHsymposium: Gore Joins Vascular and Endovascular Leaders in Recognizing the 2014 Pioneers in Performance for North America

Leading Practitioners and Researchers from North America Commended for Commitment to Advancing Vascular and Endovascular Therapy

FLAGSTAFF, Ariz.--W. L. Gore & Associates (Gore) joined with leaders across the vascular and endovascular community in honoring four North American physicians as Pioneers in Performance. The biennial award acknowledges exceptional work in the field of vascular and endovascular therapy, including aortic and lower-limb bypass and dialysis access surgery.

New Data from EVOLVE Clinical Program Demonstrate Synergy Bioabsorbable Polymer Stent Meets Key Performance Endpoints

EVOLVE II Trial Represents the First Successful U.S. Pivotal Trial of a Bioabsorbable Polymer Stent
MARLBOROUGH, Mass., (Nov. 19, 2014) – In the first successful U.S. pivotal trial of a bioabsorbable polymer stent, the Boston Scientific Synergy Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent System met its primary endpoint in this non-inferiority study, which evaluated the one-year rate of target lesion failure (TLF).

Spectranetics to Participate in First Annual Innovation and Investment Roundtable at VEITHsymposium in NYC

New Standard in Care for Treatment of In-Stent Restenosis (ISR) Featured at Breakfast Symposium Showcasing Clinical Data and Practice Application

Two New Research Studies Provide Further Support for the Potential Role of CSL112 in the Reduction of Early Recurrent Cardiovascular Events Following Myocardial Infarction

KING OF PRUSSIA, Pa., Nov. 18, 2014 — Two research studies presented today at the American Heart Association Scientific Sessions in Chicago provide further understanding of the mechanisms by which CSL112, a novel formulation of apolipoprotein A-1 (apoA-1), may reduce the high incidence of early recurrent cardiovascular events seen in post MI patients. Early recurrent cardiovascular events are associated with high morbidity and mortality, and reducing early events is an important target for new therapies.

Heart Muscle Inflammation and Swelling Peak Twice After Heart Attack

NEW YORK (November 17, 2014) – Results of a new study challenge the current  consensus in cardiology that peak myocardial edema, or heart muscle swelling, only occurs just after a myocardial infarction, or heart attack. In the study, presented as a Late-Breaking Clinical Trial at the American Heart Association (AHA) Scientific Sessions 2014 and published simultaneously in the Journal of the American College of Cardiology (JACC), scientists discovered a second wave of swelling and inflammation occurs within a week of a heart attack.

Zoll Announces the Acquisition of Philips InnerCool Temperature Management

November 17, 2014—CHELMSFORD, Mass.—ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that it has signed an agreement to purchase substantially all of the assets of Philips’ InnerCool™ temperature management business, which includes catheter-based endovascular and surface temperature management technologies designed to improve outcomes for patients with a variety of temperature management-related needs.

Research Uncovers New Way to Help Predict Outcomes for TAVR Patients

A retrospective analysis from the Minneapolis Heart Institute Foundation reveals that tricuspid regurgitation (TR) can help doctors predict which patients may have poor outcomes from the TAVR procedure

Positive Results from HARMONIZE (ZS004), a Second Phase 3 Clinical Trial of ZS-9 in Patients with Hyperkalemia, Presented at the AHA Scientific Sessions With Simultaneous Publication of Results in JAMA

Coppell, Texas – November 17, 2014 – ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today presented detailed results from HARMONIZE (ZS004) at the late-breaking Clinical Science Special Reports Session of the American Heart Association Scientific Sessions. HARMONIZE is the second positive Phase 3 clinical trial of ZS-9 (sodium zirconium cyclosilicate) for the treatment of hyperkalemia, a life threatening condition characterized by abnormally high concentrations of potassium in the blood (serum K+ ≥5.1 mEq/L).

Back to top